3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gliosarcoma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
Paclitaxel
7
Specimen Handling
6
Radiotherapy
4
Magnetic Resonance Spectroscopy
4
Biopsy
4
pembrolizumab
3
Taxes
3
Nivolumab
3
Carboplatin
3
trastuzumab deruxtecan
2
olaparib
2
ceralasertib
2
aflibercept
2
X-Rays
2
Psychiatric Rehabilitation
2
Irinotecan
2
Ipilimumab
2
Immunoglobulin G
2
Ifosfamide
2
Gene Expression Profiling
2
Fulvestrant
2
Filgrastim
2
Fentanyl
2
Doxorubicin
2
Bevacizumab
2
trifluridine tipiracil drug combination
1
toripalimab
1
tinostamustine
1
spartalizumab
1
selinexor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
tinostamustine
×
Sarcoma
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts